sifalimumab

Sifalimumab is a fully human monoclonal antibody developed for the treatment of autoimmune diseases, primarily systemic lupus erythematosus (SLE), as well as dermatomyositis and polymyositis. It targets and neutralizes multiple subtypes of interferon-alpha (IFN-α), a cytokine implicated in the pathogenesis and disease activity of SLE and other autoimmune disorders. By binding to IFN-α, sifalimumab prevents its interaction with the type I interferon receptor (specifically IFNAR1), thereby inhibiting downstream signaling pathways such as JAK/STAT that drive immune dysregulation. Clinical trials demonstrated that sifalimumab could reduce disease activity in SLE patients who had inadequate responses to standard therapies[1][2][3][4][5][6]. However, development was discontinued by AstraZeneca/MedImmune[7].

Other names

sifalimumab